<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093933</url>
  </required_header>
  <id_info>
    <org_study_id>1242-035</org_study_id>
    <secondary_id>2020-005941-18</secondary_id>
    <secondary_id>MK-1242-035</secondary_id>
    <nct_id>NCT05093933</nct_id>
  </id_info>
  <brief_title>A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)</brief_title>
  <acronym>VICTOR</acronym>
  <official_title>A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of vericiguat in&#xD;
      participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically&#xD;
      those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart&#xD;
      failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that&#xD;
      vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart&#xD;
      failure hospitalization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization</measure>
    <time_frame>From date of randomization until the date of first occurrence of a CV death or HF hospitalization, assessed up to approximately 40 months</time_frame>
    <description>The first event of CV death or HF hospitalization as confirmed by a clinical events committee (CEC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of CV Death</measure>
    <time_frame>From date of randomization until the date of first occurrence of a CV death, assessed up to approximately 40 months</time_frame>
    <description>The first event of CV death as confirmed by a CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of HF Hospitalization</measure>
    <time_frame>From date of randomization until the date of first occurrence of a HF hospitalization, assessed up to approximately 40 months</time_frame>
    <description>The first event of HF hospitalization as confirmed by a CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Total HF Hospitalizations (Including First and Recurrent Events)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>All events of HF hospitalization as confirmed by a CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization</measure>
    <time_frame>From date of randomization until the date of first occurrence of death or HF hospitalization, assessed up to approximately 40 months</time_frame>
    <description>The first event of death due to any cause or HF hospitalization as confirmed by a CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to All-Cause Mortality</measure>
    <time_frame>From date of randomization until the date of death, assessed up to approximately 40 months</time_frame>
    <description>The first event of death due to any cause as confirmed by a CEC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Experienced One or More Selected Nonserious Adverse Events (NSAEs)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Selected NSAEs are nonserious AEs that meet any of the following criteria: AEs that lead to study intervention dose modification or discontinuation, AEs that lead to withdrawal from the study, or coronavirus disease (COVID-19) disease-related AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced One or More Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, as judged medically or scientifically, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced One or More Events of Clinical Interest (ECIs)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>Events of clinical interest will include: 1) Potential drug-induced liver injury (DILI) events defined as: elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory value that is greater than or equal to 3X the upper limit of normal (ULN) and an elevated total bilirubin laboratory value that is greater than or equal to 2X the ULN and, at the same time, an alkaline phosphatase laboratory value that is less than 2X the ULN, as determined by way of protocol specified laboratory testing or unscheduled laboratory testing, 2) Symptomatic hypotension 3) Anemia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Chronic Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Vericiguat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive a starting matching placebo to vericiguat dose of 2.5 mg taken orally once daily. The matching placebo dose will be sham titrated to 5 mg and to 10 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vericiguat</intervention_name>
    <description>2.5, 5.0, or 10.0 mg orally once daily</description>
    <arm_group_label>Vericiguat</arm_group_label>
    <other_name>MK-1242</other_name>
    <other_name>BAY 1021189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of chronic HF [New York Heart Association (NYHA) Class II to IV] on&#xD;
             guideline-directed medical therapy for heart failure (GDMT) with no HF hospitalization&#xD;
             within 6 months or outpatient IV diuretic use within 3 months before randomization.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) of â‰¤40%, assessed within 12 months before&#xD;
             randomization by any imaging method.&#xD;
&#xD;
          -  Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, is not a woman of childbearing potential (WOCBP), or is a WOCBP and&#xD;
             agrees to follow contraceptive guidance during the study intervention period and for&#xD;
             at least 1 month after the last dose of study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Awaiting heart transplantation, is receiving continuous IV infusion of an inotrope, or&#xD;
             has or anticipates receiving an implanted ventricular assist device.&#xD;
&#xD;
          -  Amyloidosis or sarcoidosis.&#xD;
&#xD;
          -  Primary valvular heart disease requiring surgical procedure or intervention or has&#xD;
             undergone a vascular surgical procedure or intervention within 3 months before&#xD;
             randomization.&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Acute myocarditis or Takotsubo cardiomyopathy.&#xD;
&#xD;
          -  History of heart transplant.&#xD;
&#xD;
          -  Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia&#xD;
&#xD;
          -  Acute coronary syndrome, or undergone coronary artery bypass grafting (CABG) or&#xD;
             percutaneous coronary intervention (PCI) within 3 months before randomization.&#xD;
&#xD;
          -  History of symptomatic carotid stenosis, transient ischemic attack (TIA), or stroke&#xD;
             within 3 months before randomization.&#xD;
&#xD;
          -  Malignancy or other noncardiac condition limiting life expectancy to &lt;3 years.&#xD;
&#xD;
          -  Requires continuous home oxygen for severe pulmonary disease.&#xD;
&#xD;
          -  Interstitial lung disease.&#xD;
&#xD;
          -  Discontinuation or dose modification of GDMT or vericiguat within 4 weeks before&#xD;
             randomization.&#xD;
&#xD;
          -  Recent history (within the last year) of drug or alcohol abuse or dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Cardiovascular - Alexander City ( Site 0038)</name>
      <address>
        <city>Alexander City</city>
        <state>Alabama</state>
        <zip>35010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>256-215-5323</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Trials Inc ( Site 0006)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-280-4220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center Inc ( Site 0011)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-825-6588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Center of South Florida ( Site 0074)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-275-8808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research, LLC ( Site 0016)</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>904-407-0302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research of Northwest Indiana ( Site 0036)</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>219-934-4248</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Heart and Vascular, P.C.-Clinical Trials Unit ( Site 0029)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-741-0911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amici Clinical Research LLC-Research ( Site 0037)</name>
      <address>
        <city>Raritan</city>
        <state>New Jersey</state>
        <zip>08869</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-369-3480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apex Research Foundation ( Site 0001)</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>731-423-8200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Houston Area Clinical Trial Consultants ( Site 0014)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>832-431-3587</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dominion Medical Associates, Inc. ( Site 0089)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-249-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Research Group ( Site 0452)</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61738765688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef Braunau ( Site 0354)</name>
      <address>
        <city>Braunau</city>
        <state>Oberosterreich</state>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+43 7722 804 0</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Floridsdorf-Karl Landsteiner Institute for Cardiovascular and Critical Care Research c/o Dep</name>
      <address>
        <city>Wien</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+431277000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CoroMed ( Site 1867)</name>
      <address>
        <city>PÃ©cs</city>
        <state>Baranya</state>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36306531898</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Practice - Dr. Lakatos Ferenc ( Site 1854)</name>
      <address>
        <city>BÃ©kÃ©scsaba</city>
        <state>Bekes</state>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3666327633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OEC Clinical Research - Zalaegerszeg ( Site 1864)</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36 1 436 7344</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research and Cardiovascular Corp. ( Site 3152)</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>787-295-0546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caparra Internal Medicine ( Site 3155)</name>
      <address>
        <city>Rio Grande</city>
        <zip>00745</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>787-657-0131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Barcelona ( Site 3655)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34686160721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario RamÃ³n y Cajal ( Site 3662)</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368954</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL CLINICO DE VALENCIA ( Site 3656)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 961973520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme ( Site 3654)</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955015878</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Hungary</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

